Pediatric Oral-Dissolving Drug Delivery Platforms: Current Evidence and Clinical Implications

Abstract

Pediatric oral-dissolving drug delivery platforms (ODDPs) represent a significant advancement in the pharmacological management of children, offering improved compliance, rapid onset of action, and reduced risk of aspiration. This review critically examines the epidemiology, pathophysiology, risk factors, clinical features, diagnosis, management strategies, recent advances, and guideline recommendations pertaining to pediatric ODDPs. Drawing on latest evidence and guidelines, we synthesize the clinical and practical implications for healthcare professionals, emphasizing the importance of tailored drug delivery approaches in pediatric populations.

Introduction

The administration of pharmacological agents to pediatric patients presents unique challenges due to developmental, physiological, and behavioral differences compared to adults. Traditional oral dosage forms may be unsuitable for children owing to swallowing difficulties, taste aversion, and risk of choking. Oral-dissolving drug delivery platforms (ODDPs), including orally disintegrating tablets (ODTs) and films (ODFs), are specifically engineered to disintegrate rapidly upon contact with saliva, eliminating the need for water and facilitating ease of administration. The growing body of evidence underscores their role in enhancing adherence, optimizing therapeutic outcomes, and mitigating administration-related risks in pediatric care.

Epidemiology / Disease Burden

The prevalence of medication non-adherence in pediatric populations ranges from 30% to 70%, often exacerbated by issues related to palatability, difficulty swallowing, and complex dosing regimens. Conditions necessitating chronic medication—such as epilepsy, attention deficit hyperactivity disorder (ADHD), asthma, and infectious diseases—frequently require precise dosing and reliable administration, which can be compromised by traditional dosage forms. Global data indicate that up to 40% of children experience oral administration challenges, highlighting a substantial unmet need for alternative drug delivery systems that address these barriers and reduce the disease burden associated with poor medication adherence.

Pathophysiology

Pediatric patients exhibit significant anatomical and physiological differences compared to adults, including underdeveloped swallowing reflexes, lower salivary flow rates, and immature gastrointestinal (GI) tract function. These factors influence the pharmacokinetics and pharmacodynamics of oral medications. Children, especially those under six years of age, are at increased risk of aspiration, choking, and esophageal irritation when exposed to conventional tablets or capsules. The pathophysiological rationale for ODDPs is grounded in their ability to bypass the need for swallowing, facilitate disintegration directly in the oral cavity, and ensure rapid drug absorption via the buccal or sublingual mucosa, thereby providing both safety and efficacy advantages.

Risk Factors

Risk factors influencing the suitability of oral drug formulations in pediatric patients include age (infants and toddlers are at greatest risk), neurodevelopmental delays, dysphagia, poor gag reflex, and behavioral disorders. Other contributing factors encompass taste sensitivity, aversion to bitter flavors, and previous traumatic experiences with medication administration. These risk factors underscore the necessity for palatable, easy-to-administer, and safe drug delivery platforms tailored to the pediatric population.

Clinical Features

Clinical presentation of medication administration difficulties in children may include refusal to take medication, gagging, vomiting, incomplete dosing, and anxiety or behavioral disturbances at medication times. Such features can lead to suboptimal therapeutic outcomes, increased healthcare utilization, and caregiver distress. The use of ODDPs has been associated with improved cooperation, enhanced acceptability, and reduced incidence of adverse administration events in clinical settings.

Diagnosis

Diagnosis of challenges related to oral drug administration in pediatric patients is primarily clinical, based on detailed history and observation. Assessment tools, such as the Pediatric Oral Medicine Administration Assessment (POMAA), can systematically evaluate swallowing ability, taste response, and behavioral reactions. Collaboration with speech and language therapists may be warranted in cases with significant dysphagia or neurodevelopmental comorbidities.

Treatment & Management

Management strategies encompass selection of age-appropriate formulations, caregiver education, and behavioral interventions to promote medication acceptance. ODDPs provide a practical solution by offering rapid disintegration, pleasant taste masking, and ease of administration without water. Clinical protocols often recommend ODTs or ODFs as first-line options in children with a history of swallowing difficulties or poor compliance. Individualized dosing and monitoring are essential to ensure therapeutic efficacy and minimize the risk of dosing errors, particularly in neonates and infants.

Recent Advances / Emerging Therapies

Recent innovations in ODDPs include the use of nanotechnology for enhanced drug solubility, polymer-based films with improved mechanical properties, and 3D-printed ODTs allowing precision dosing. Taste-masking technologies, such as microencapsulation and cyclodextrin complexes, have significantly advanced palatability for pediatric patients. Regulatory agencies are increasingly recognizing the importance of pediatric-specific formulations, with guidelines encouraging pharmaceutical development tailored to the unique needs of children. Additionally, advances in pharmacogenomics are beginning to inform personalized drug delivery strategies, optimizing both efficacy and safety profiles for pediatric patients.

Guideline Recommendations

Leading pediatric and pharmacological societies recommend prioritizing ODDPs for children who have difficulty swallowing, are at risk of aspiration, or require medication administration outside of healthcare settings. Guidelines emphasize the importance of palatability, dosing accuracy, and caregiver involvement in medication administration. The American Academy of Pediatrics (AAP) and European Medicines Agency (EMA) both advocate for the development and use of age-appropriate, orally disintegrating formulations, particularly for chronic and high-risk conditions. Clinical decision-making should be informed by patient-specific factors, with ongoing evaluation of adherence and therapeutic response.

Conclusion

Pediatric oral-dissolving drug delivery platforms represent a pivotal advancement in pediatric pharmacotherapy, offering substantial benefits in terms of safety, efficacy, and patient acceptance. Evidence supports the integration of ODDPs into routine clinical practice for children with swallowing difficulties and those requiring improved medication adherence. Ongoing research and innovation are expected to further enhance the therapeutic potential and accessibility of these platforms, underscoring their vital role in optimizing pediatric healthcare outcomes.